glp 1 for prader willi New commentary offers practical guidance on GLP-1 use in Prader-Willi syndrome glp 1 prader willi Glucagon-like

Description

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI

While this approach may work short term, it often triggers the bodys natural defense mechanisms

Approved in 1964 for the management of hypertension, propranolol is now used for a wide range of cardiovascular diseases, including ischemic heart disease, angina pectoris, arrhythmias, and myocardial infarction, as well as non cardiovascular conditions, including migraine, tremors and anxiety